News
XRTX
0.9200
-2.14%
-0.0201
BRIEF-Xortx Completes Screening $ Enrollment In Bridging Pharmacokinetics Study
Reuters · 2d ago
XORTX Announces Completion Of Screening And Enrollment In Bridging Pharmacokinetics Study
Benzinga · 2d ago
XORTX Therapeutics Receives Nasdaq Non-Compliance Notice
XORTX Therapeutics Receives Nasdaq Non-Compliance Notice
MT Newswires · 2d ago
BRIEF-XORTX Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Reuters · 4d ago
XORTX Presents New Proof of Concept Data at American Society of Nephrology
● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increasein Total Kidney Weight in Polycystic Kidney Disease ● CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: X...
GlobeNewswire · 11/03 21:00
XORTX Announces Participation at Upcoming Investor Conferences
CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressiv...
GlobeNewswire · 11/03 14:15
BRIEF-Xortx Receives Further No Objection Letter From Health Canada
Reuters · 10/26 11:11
XORTX Receives Further No Objection Letter From Health Canada
Benzinga · 10/26 11:08
XORTX Announces Closing of US$5 Million Public Offering
CALGARY, Alberta, Oct. 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressiv...
GlobeNewswire · 10/07 22:02
XORTX Therapeutics prices $5M underwritten public offering
Clinical pharmaceutical company XORTX Therapeutics (XRTX) priced a $5M underwritten public offering...
Seekingalpha · 10/04 16:17
Inhibrx, Immunovant top healthcare gainers; Biohaven, KalVista lead losers' pack
Gainers: Inhibrx (INBX) +27%. Immunovant IMVT +26%</fo...
Seekingalpha · 10/04 14:05
XORTX Announces $5M Public Offering
XORTX Therapeutics Inc. (&#34;XORTX&#34; or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat
Benzinga · 10/04 12:31
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
Benzinga · 09/26 07:43
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day extension to March 13, 2023 to regain compliance.
Benzinga · 09/23 16:16
BRIEF-Xortx Completes Positive Pre-Phase 3 Meeting With U.S. FDA
BRIEF-Xortx Completes Positive Pre-Phase 3 Meeting With U.S. FDA
Reuters · 09/19 11:17
XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration
CALGARY, Alberta, Sept. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical development stage pharmaceutical company focused on developing innovative therapies to treat pr...
GlobeNewswire · 09/19 11:00
XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2022
Hyperuricemia is Associated with Accelerated Polycystic Kidney Disease (“PKD”) InjuryCALGARY, Alberta, Sept. 01, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical...
GlobeNewswire · 09/01 11:00
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.
Benzinga · 08/25 09:18
Why Citi Trends Is Trading Lower By 17%, Here Are 47 Stocks Moving In Wednesday's Mid-Day Session
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 77% to $2.35. Bright Minds priced overnight marketed offering of 2.858 million units at $1.40 per unit.
Benzinga · 08/24 16:32
What Is Going on With Signify Health (SGFY) Stock Today?
Investor Place · 08/22 15:54
More
Webull provides a variety of real-time XRTX stock news. You can receive the latest news about Xortx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan (rare) disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) associated with coronavirus infection. Its three lead product candidates are XRx-008, for the treatment of ADPKD; XRx-101, to treat AKI associated with Coronavirus / COVID-19 infection, AKI and associated health consequences. In addition, XRx-225 is a pre-clinical stage program for type 2 diabetic nephropathy. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company is evaluating xanthine oxidase inhibitor candidates for the XRx-225 program to treat T2DN.